Placebo controlled trials in over 25,000 women showed that tamoxifen reduced breast cancer risk by about 40% and osteoporotic fracture risk by about 32%. Similarly placebo controlled trials in nearly 18,000 women showed that raloxifene reduced breast cancer risk by 44-72% and osteoporotic fractures risk by 30-50%. A direct comparison of tamoxifen with raloxifene showed similar risk reduction for breast cancer and osteoporotic fractures with less toxicity for raloxifene. © 2006 BioMed Central Ltd.
CITATION STYLE
Powles, T. J. (2006). Prevetion of breast cancer using selective oestrogen receptor modulators (SERMs). Breast Cancer Research, 8(5). https://doi.org/10.1186/bcr1601
Mendeley helps you to discover research relevant for your work.